CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 11, 2021-- bluebird bio, Inc. (Nasdaq: BLUE) announced its intent to separate its severe genetic disease and...
Separate
Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with...
